Biologics, Inc. Adds Chief Operating Officer to Executive Team

CARY, N.C.--(BUSINESS WIRE)--Biologics, an integrated oncology services company, has announced that Ron Smith, Pharm.D, has joined the company as Chief Operating Officer. In his role, he will oversee all operational initiatives throughout Biologics with particular emphasis within Care Integration, Oncology Pharmacy, Patient Access and Clinical Research Services.

"I am thrilled Ron is joining our team," said Stuart Frantz, President & CEO. "Ron and I have known each other for over five years and he is a perfect fit with our purposeful mission. We are experiencing exceptional growth and Ron's intelligence, leadership skills and clinical background will assist Biologics in navigating our expansion."

Dr. Smith previously served as Chief Operating Officer at Physicians Pharmacy Alliance (PPA) where he led the development of PPA's medication management service to patient-centered medical homes, hospital health systems and key managed care clients. He began his professional career in health care at BlueCross BlueShield of North Carolina, serving in a number of leadership positions that focused on developing new care delivery and payment models to promote quality care and preventative health.

"It is clear that Biologics' culture embodies a sense of energy and compassion that ultimately has a positive impact on the lives of those battling cancer," said Smith. "I am excited for the opportunity to be a part of this team and look forward to supporting our growth initiatives so that we may deliver care to more people."

Dr. Smith earned his master's in business administration and doctorate in pharmacy, cum laude from Campbell University.

About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient's best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. For more information, visit

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.